Effects of oral N-acetylcysteine on walking capaci... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Effects of oral N-acetylcysteine on walking capacity, leg reactive hyperemia, and inflammatory and angiogenic mediators in patients with intermittent claudication

Full text
Author(s):
da Silva, Jr., Natan D. [1] ; Roseguini, Bruno T. [2] ; Chehuen, Marcel [1] ; Fernandes, Tiago [1] ; Mota, Gloria F. [1] ; Martin, Priscila K. M. [3] ; Han, Sang W. [3] ; Forjaz, Claudia L. M. [1] ; Wolosker, Nelson [4] ; de Oliveira, Edilamar M. [1]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Sch Phys Educ & Sport, Dept Biodynam, BR-05508900 Sao Paulo, SP - Brazil
[2] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 - USA
[3] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo - Brazil
[4] Univ Sao Paulo, Sch Med, Dept Surg, Vasc & Endovasc Div, BR-05508900 Sao Paulo, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY; v. 309, n. 5, p. H897-H905, SEP 1 2015.
Web of Science Citations: 7
Abstract

Increased oxidative stress and inflammation contribute to impaired walking capacity and endothelial dysfunction in patients with intermittent claudication (IC). The goal of the study was to determine the effects of oral treatment with the antioxidant N-acetylcysteine (NAC) on walking capacity, leg postocclusive reactive hyperemia, circulating levels of inflammatory mediators, and whole blood expression of angiogenic mediators in patients with IC. Following a double-blinded randomized crossover design, 10 patients with IC received NAC (1,800 mg/day for 4 days plus 2,700 mg before the experimental session) and placebo (PLA) before undergoing a graded treadmill exercise test. Leg postocclusive reactive hyperemia was assessed before and after the test. Blood samples were taken before and after NAC or PLA ingestions and 5 and 30 min after the exercise test for the analysis of circulating inflammatory and angiogenic markers. Although NAC increased the plasma ratio of reduced to oxidized glutathione, there were no differences between experimental sessions for walking tolerance and postocclusive reactive hyperemia. Plasma concentrations of soluble vascular cell adhesion protein-1, monocyte chemotactic protein-1, and endothelin-1 increased similarly following maximal exercise after PLA and NAC (P < 0.001). Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response. Similarly, exercise-induced changes in whole blood expression of VEGF, endothelial nitric oxide synthase and phosphatidylinositol 3-kinase R2 were blunted after NAC. In conclusion, oral NAC does not increase walking tolerance or leg blood flow in patients with IC. In addition, oral NAC prevents maximal exercise-induced increase in the expression of circulating microRNA-126 and other angiogenic mediators in patients with IC. (AU)

FAPESP's process: 13/05883-8 - Effects of oral N-acetylcysteine supplementation on walking capacity, vasodilatory capacity and oxidative stress markers in patients with peripheral arterial disease
Grantee:Nelson Wolosker
Support Opportunities: Regular Research Grants